---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-003555"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:48:29.929579+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atara Bio closes $31M royalty financing liability with HCR Molag Fund

## Summary
- Closed $31M royalty financing with HCR Molag Fund on Dec 30, 2022; recorded net of transaction costs.
- Financing stems from Purchase and Sale Agreement dated Dec 20, 2022, previously disclosed.
- Transaction creates a direct financial obligation under Item 2.03 of Form 8-K.
- HCR Molag Fund, L.P. is the counterparty; net proceeds used for general corporate purposes (not specified).

## SEC filing metadata
- accession: 0001193125-23-003555
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.03, 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/0001193125-23-003555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/d444758d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-003555
- JSON: https://secwatch.observer/filing/0001193125-23-003555.json
- Plain text: https://secwatch.observer/filing/0001193125-23-003555.txt

## Key facts
- Debt Financings
  Atara Biotherapeutics, Inc. incurred debt of $31,000,000, net of certain transaction costs with HCR Molag Fund, L.P..
  - Principal: $31,000,000, net of certain transaction costs
  - Counterparty: HCR Molag Fund, L.P.
  - Event: incurrence
  source text: On December 30, 2022, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), and HCR Molag Fund, L.P., a Delaware limited partnership (“HCR”), closed the transactions contemplated by that certain Purchase and Sale Agreement dated December 20, 2022 by and between the Company and HCR.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/0001193125-23-003555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.